Novo Nordisk A/S to Restart Liraglutide Obesity Studies

Reuters -- Novo Nordisk (NOVOb.CO) will re-launch late-stage trials of its new diabetes drug liraglutide for treating obesity, the company said on Tuesday in a vote of confidence in the drug that has overcome safety concerns.

Back to news